Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$173.04 USD

173.04
1,581,725

-0.88 (-0.51%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Ionis (IONS) Q3 Loss Wider Than Expected, Sales Beat Estimates

by Zacks Equity Research

Ionis (IONS) incurs a wider-than-expected third-quarter loss. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

Biogen Inc. (BIIB) Rises But Trails Market: What Investors Should Know

by Zacks Equity Research

The latest trading day saw Biogen Inc. (BIIB) settling at $237.30, representing a +1.19% change from its previous close.

CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors will focus on CRISPR Therapeutics' (CRSP) pipeline, specifically regulatory updates on lead candidate exa-cel.

Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Eli Lilly's (LLY) third-quarter conference call, investor focus is likely to be on the sales of its new diabetes drug, Mounjaro.

Amgen (AMGN) to Report Q3 Earnings: Will It Beat Estimates?

by Zacks Equity Research

Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Pfizer (PFE) to Report Q3 Earnings: Here's What to Expect

by Zacks Equity Research

Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.

Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market

by Zacks Equity Research

The latest trading day saw Biogen Inc. (BIIB) settling at $253.39, representing a -1.58% change from its previous close.

What's in Store for Bristol-Myers (BMY) in Q3 Earnings?

by Zacks Equity Research

Investors are likely to focus on Opdivo's demand along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results.

Merck (MRK) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.

Novartis (NVS) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Investor focus is likely to be on the top and bottom-line numbers, and updates on guidance post-Sandoz spin-off when Novartis (NVS) reports its third-quarter results.

Sundeep Ganoria headshot

Sage's (SAGE) Huntington's Disease Drug Gets FDA's Orphan Tag

by Sundeep Ganoria

The FDA grants orphan drug designation to Sage Therapeutics' (SAGE) SAGE-718 for treating Huntington's disease. The designation will help incentivize the development of the candidate.

5 Biotech Stocks Set to Outpace Q3 Earnings Estimates

by Zacks Equity Research

Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.

Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know

by Zacks Equity Research

In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $267.43, denoting a -0.19% change from the preceding trading day.

Roche's (RHHBY) MS Drug Reduces Brain Lesions in Phase II Study

by Zacks Equity Research

Roche (RHHBY) presents new data from a phase II study, which shows that fenebrutinib is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis.

Annovis (ANVS) AD Study to Continue as Planned, Shares Rise

by Zacks Equity Research

Annovis (ANVS) gains on the release of interim independent analysis, indicating that the ongoing phase II/III study in Alzheimer's Disease is sufficiently powered to continue as planned without any additional patients.

Wall Street Analysts See a 25.44% Upside in Biogen Inc. (BIIB): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Biogen Inc. (BIIB) points to a 25.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Will Biogen Inc. (BIIB) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Biogen Inc. (BIIB) Advances But Underperforms Market: Key Facts

by Zacks Equity Research

In the most recent trading session, Biogen Inc. (BIIB) closed at $264.21, indicating a +0.36% shift from the previous trading day.

Bristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 B

by Zacks Equity Research

Bristol Myers (BMY) to offset its declining revenues from top drugs with the acquisition of Mirati Therapeutics, which will add lung cancer drug Krazati to its portfolio.

Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Biogen Inc. (BIIB) closed at $252.86 in the latest trading session, marking a -1.61% move from the prior day.

Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs

by Zacks Equity Research

Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases.

Intercept Pharmaceuticals (ICPT) Surges on Acquisition Deal

by Zacks Equity Research

Intercept Pharmaceuticals (ICPT) gains an acquisition deal from Alfasigma for $19.00 per share in cash.

Ionis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5%

by Zacks Equity Research

Ionis (IONS) reports positive phase III study results, supporting the benefits of olezarsen to treat familial chylomicronemia syndrome (FCS), a rare genetic disorder.